A Single Arm, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment Naïve Adults With Chronic Hepatitis C Virus (HCV) Genotypes 1-6 Infection and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤ 1
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 07 Mar 2018
At a glance
- Drugs Glecaprevir/pibrentasvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors AbbVie
- 28 Feb 2018 Status changed from recruiting to active, no longer recruiting.
- 14 Aug 2017 Status changed from not yet recruiting to recruiting.
- 14 Jul 2017 New trial record